ABBV-744 in clinical trials for non-small cell lung cancer (NSCLC) Options
The existing work examined the potential of utilizing ARV-825 and ABBV-744 to raise the effectiveness of tamoxifen or fulvestrant plus palbociclib. ARV-825 was effective in equally p53 wild-style (WT) breast tumor cells and in cells missing useful p53 possibly by itself or in combination with tamoxifen, whilst the effectiveness of ABBV-744 was limi